Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SANA 
Sana Biotechnology Inc (SANA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/02/2025: SANA (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $8.57
1 Year Target Price $8.57
| 4 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 131.21% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.06B USD | Price to earnings Ratio - | 1Y Target Price 8.57 |
Price to earnings Ratio - | 1Y Target Price 8.57 | ||
Volume (30-day avg) 8 | Beta 1.95 | 52 Weeks Range 1.26 - 6.55 | Updated Date 12/3/2025 |
52 Weeks Range 1.26 - 6.55 | Updated Date 12/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.95 |
Earnings Date
Report Date 2025-11-05 | When - | Estimate -0.1882 | Actual -0.15 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -23.9% | Return on Equity (TTM) -96.11% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 994646480 | Price to Sales(TTM) - |
Enterprise Value 994646480 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.08 | Shares Outstanding 266366120 | Shares Floating 176992296 |
Shares Outstanding 266366120 | Shares Floating 176992296 | ||
Percent Insiders 6.95 | Percent Institutions 79.47 |
Upturn AI SWOT
Sana Biotechnology Inc
Company Overview
History and Background
Sana Biotechnology Inc. was founded in 2018. It's focused on developing engineered cells as medicines, aiming to treat diseases by modifying cells in the body or replacing damaged cells.
Core Business Areas
- In Vivo Delivery: Developing technologies to deliver genes directly into cells within the body.
- Ex Vivo Cell Engineering: Engineering cells outside the body before transplanting them back into the patient.
- Hypoimmune Platform: Creating cells that are invisible to the immune system to avoid rejection.
Leadership and Structure
The leadership team includes Steve Harr as CEO. The organizational structure is typical of a biotechnology company, with research, development, and clinical operations divisions.
Top Products and Market Share
Key Offerings
- SC291 (CD19 CAR T cell therapy): An ex vivo CAR T-cell therapy being developed for the treatment of relapsed or refractory B-cell lymphomas. Competitors include Gilead (Kite Pharma) with Yescarta and Novartis with Kymriah. No current market share data available as it is in clinical development.
- SC262 (allogeneic CAR T): An allogeneic (donor-derived) CAR T cell therapy utilizing Sana's hypoimmune platform. No current market share data available as it is in clinical development.
Market Dynamics
Industry Overview
The cell and gene therapy industry is rapidly growing, driven by technological advancements and increasing success in treating previously untreatable diseases. However, it faces challenges related to manufacturing scalability, high costs, and regulatory hurdles.
Positioning
Sana Biotechnology Inc. is positioned as an innovator in cell and gene therapy, with a focus on in vivo delivery and hypoimmune cell technology. Its competitive advantage lies in its differentiated platform and its potential to address limitations of existing cell therapies such as CAR-T.
Total Addressable Market (TAM)
The total addressable market for cell and gene therapies is estimated to reach hundreds of billions of dollars. Sana is positioned to capture a portion of this TAM through its novel technologies, focused on specific indications with high unmet need.
Upturn SWOT Analysis
Strengths
- Innovative platform technologies (in vivo delivery, hypoimmune cells)
- Strong intellectual property portfolio
- Experienced management team
- Significant funding
Weaknesses
- Early stage of development, with no products currently on the market
- High cash burn rate
- Reliance on successful clinical trial outcomes
- Manufacturing challenges inherent to cell and gene therapy
Opportunities
- Expansion of pipeline into new therapeutic areas
- Partnerships with pharmaceutical companies
- Advancements in manufacturing technologies
- Positive clinical trial results leading to regulatory approvals
Threats
- Competition from established cell and gene therapy companies
- Regulatory hurdles and delays
- Clinical trial failures
- Adverse events associated with cell and gene therapies
Competitors and Market Share
Key Competitors
- GILD
- NVS
- CRSP
- EDIT
- BEAM
Competitive Landscape
Sana's competitive advantages lie in its novel technology platforms, particularly its in vivo delivery and hypoimmune cell technologies. However, it faces competition from established companies with approved products and larger financial resources. The gene editing competition is considered a player due to the similar therapeutic modality used.
Growth Trajectory and Initiatives
Historical Growth: Sana Biotechnology Inc.'s growth has been primarily focused on advancing its research and development programs and building its platform technologies.
Future Projections: Future growth depends on clinical trial success and potential partnerships. Analyst projections vary significantly due to the inherent risks in biotech development.
Recent Initiatives: Recent initiatives include advancing clinical trials for its lead programs and expanding its manufacturing capabilities.
Summary
Sana Biotechnology is an early-stage biotech company with innovative cell and gene therapy platforms. Its strengths lie in its novel technologies and experienced management. However, it faces significant risks related to clinical trial success and competition. The company needs to successfully navigate regulatory hurdles and demonstrate clinical efficacy to realize its full potential.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Sana Biotechnology Inc. SEC Filings
- Company Website
- Analyst Reports
- Industry Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sana Biotechnology Inc
Exchange NASDAQ | Headquaters Seattle, WA, United States | ||
IPO Launch date 2021-02-04 | President, CEO & Director Dr. Steven D. Harr M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 194 | Website https://www.sana.com |
Full time employees 194 | Website https://www.sana.com | ||
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline consist of UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SC291, a HIP-modified allogeneic CD19-dirtected allogeneic CAR T cell product candidate which is in phase 1 clinical trial to treat systemic lupus erythematosus and ANCA-associated vasculitis, as well as in preclinical trial to treat other indications and b-cell mediated autoimmune disease; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. It also develops SC262, a hypoimmune-modified CD22-directed allogeneic CAR T program, which is in phase 1 to treat non-Hodgkin's lymphoma; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.